SCHEMBL1712827

SCHEMBL1712827

COCOCCN1C(=O)CCC1CO

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 2/20 0.47
▸ BRD4 O60885 1/20 0.33
▸ PTGER4 P35408 3/20 0.32
▸ PTGER3 P43115 3/20 0.32
▸ PTGER2 P43116 3/20 0.32
▸ PER2 O15055 3/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ USP2 O75604 1/20 0.30
▸ CHRM2 P08172 3/20 0.30
▸ CHRM4 P08173 3/20 0.30
▸ CHRM5 P08912 3/20 0.30
▸ CHRM1 P11229 3/20 0.30
▸ CHRM3 P20309 3/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1712825 0.87 PDK2 (0.45) PDK2PTGER4PTGER3PTGER2CHRM2
SCHEMBL1712652 0.76 PDK2 (0.39) PDK2BRD4PTGER4PTGER3PTGER2
SCHEMBL1074993 0.74 PTGER4 (0.41) PDK2BRD4PTGER4PTGER3PTGER2
SCHEMBL1074995 0.74 PTGER4 (0.41) PDK2BRD4PTGER4PTGER3PTGER2
SCHEMBL1712920 0.74 PDK2 (0.39) PDK2BRD4PTGER4PTGER3PTGER2
SCHEMBL1712647 0.73 PDK2 (0.41) PDK2BRD4PTGER4PTGER3PTGER2
SCHEMBL11949258 0.72 L3MBTL1 (0.39) BRD4KMT2A
SCHEMBL12301049 0.72 L3MBTL1 (0.39) BRD4KMT2A
SCHEMBL11929360 0.72 L3MBTL1 (0.39) BRD4KMT2A
SCHEMBL14092774 0.72 PTGER4 (0.53) PTGER4PTGER3PTGER2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-01 — — US disclosed
US-20190177271-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2019-06-13 — — US disclosed
US-20150329491-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2015-11-19 — — US disclosed
EP-2345629-B1 FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES JAPAN TOBACCO INC (JP) 2015-06-03 — — EP disclosed
US-8871934-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2014-10-28 — — US disclosed
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (US) 2013-10-17 — — US disclosed
US-8343994-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2013-01-01 — — US disclosed
EP-2345629-A1 FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Japan Tobacco, Inc. (JP) 2011-07-20 — — EP disclosed
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof JAPAN TOBACCO INC. (JP) 2010-09-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329491-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC PDK2 8/4885BRD4 4163/4885PTGER4 4115/4885
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof FH, PCK2, PC PDK2 8/4885BRD4 4163/4885PTGER4 4115/4885
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC PDK2 8/4885BRD4 4163/4885PTGER4 4115/4885
US-20190177271-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC PDK2 8/4885BRD4 4163/4885PTGER4 4115/4885
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC PDK2 8/4885BRD4 4163/4885PTGER4 4115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback